Evidence map›Paper›PMID 37486333›Full record

ArticleACS synthetic biology2023

Targeted

Christos Skrekas, Angelo Limeta, Verena Siewers, Florian David

Open access · hybridAbstract read
In one paragraph

Article in ACS synthetic biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. CRISPR-DNA Polymerase Assisted Targeted Mutagenesis for Regulable Laboratory Evolution.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Article
  3. CRISPR/Cas9 as a Mutagenic Factor.International journal of molecular sciences · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Christos SkrekasDepartment of Life Sciences, Chalmers University of Technology, Gothenburg SE-41296, Sweden.ORCID 0000-0003-2510-495X
Angelo LimetaDepartment of Life Sciences, Chalmers University of Technology, Gothenburg SE-41296, Sweden.
Verena SiewersDepartment of Life Sciences, Chalmers University of Technology, Gothenburg SE-41296, Sweden.
Florian DavidDepartment of Life Sciences, Chalmers University of Technology, Gothenburg SE-41296, Sweden.
Chalmers University of Technology · SENovo Nordisk Foundation · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Directed evolution is a preferred strategy to improve the function of proteins such as enzymes that act as bottlenecks in metabolic pathways. Common directed evolution approaches rely on error-prone PCR-based libraries where the number of possible variants is usually limited by cellular transformation efficiencies. Targeted

Indexed as

CRISPR-Cas SystemsSaccharomyces cerevisiaeAminohydrolasesGene EditingMutagenesisMutagenesis, Site-Directedadenine deaminaseAminohydrolases

Identifiers

PMID37486333
PMCPMC10443040
OpenAlexW4385186162

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.